anti-PD-L1 antibody-drug conjugates

Anti-PD-L1 antibody-drug conjugates (ADCs) are a class of biologic therapeutics that combine a monoclonal antibody targeting Programmed Death-Ligand 1 (PD-L1) with a cytotoxic payload via a chemical linker. This modality is designed to selectively deliver potent cell-killing agents to PD-L1-expressing cancer cells, thereby increasing the therapeutic index compared to systemic chemotherapy. PD-L1 is an immune checkpoint protein frequently overexpressed in various malignancies, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and urothelial carcinoma. The primary mechanism of action involves the binding of the antibody to PD-L1, followed by internalization of the complex and intracellular release of the payload (e.g., monomethyl auristatin E), which disrupts cellular processes like microtubule assembly. Additionally, these agents may induce immunogenic cell death, further activating the tumor microenvironment. SGN-PDL1V (PF-08046054), developed by Seagen (a Pfizer subsidiary), is a prominent candidate in this class currently undergoing Phase I clinical evaluation.

Other names

PD-L1 ADCPD-L-1 ADCPD-L 1 ADCanti-PD-L1 ADCanti-PD-L-1 ADCanti-PD-L 1 ADCPD-L1-targeted antibody-drug conjugatePD-L-1-targeted antibody-drug conjugatePD-L 1-targeted antibody-drug conjugate